EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study

Breast Cancer Research and Treatment 2026

View at publisher
Authors: Diogo Alexandre Martins-Branco, Soraia Lobo-Martins, Philippe Georges Aftimos, Bernardo Pereira, Leonor Vasconcelos de Matos, Leonor Fernandes, Elsa Campôa, Guilherme Nader Marta, Michel Moreau, Donatienne Taylor, François P. Duhoux, PEDRO LUCAS MUNIZ SIMÕES
+16 more Ana Rita Garcia, Vanessa Patel, Caterina Confente, Diogo Alpuim Costa, José Pereira, Catarina Santos, Marianne Paesmans, Frederico Sarmento, Teresa Gantes Padrão, Diana Cardoso Simão, Daniel Bandarra, Berta Sousa, Margarida Brito, Andrea Gombos, Lieveke Ameye, Evandro de Azambuja
DOI: 10.1007/s10549-026-08012-5
Cited by: 1
References: 53

Fields of Study & Subjects

Advanced Breast Cancer Therapies HER2/EGFR in Cancer Research PI3K/AKT/mTOR signaling in cancer

Publication details

Journal / source
Breast Cancer Research and Treatment
Publisher
Springer Science and Business Media LLC
Volume
218
Issue
1
Publication date
1 July 2026
Language
EN